PGNY Technical Analysis & Stock Price Forecast
This article provides a technical analysis of Progyny Inc. (PGNY), indicating a "Strong Sell" consensus based on various indicators as of April 2, 2026. The stock is trading below its key moving averages, and while some oscillators like RSI suggest an oversold condition, others like MACD signal a sell. Key support and resistance levels are identified for traders.
PGNY SEC Filings - Progyny, Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Progyny (PGNY) SEC filings, including annual reports (10-K), quarterly reports (10-Q), material event reports (8-K), and insider trading forms (Form 4), along with AI-powered summaries. The content details how these filings offer insights into the company's financial performance, operational strategies in women's health and family building solutions, executive changes, and risk factors. Recent filings highlight CEO equity compensation, insider stock sales, growth outlook, and management changes.
Wall Street Zen Downgrades Progyny (NASDAQ:PGNY) to Hold
Wall Street Zen downgraded Progyny (PGNY) from "buy" to "hold," causing a share price near a 52-week low, despite the company beating Q4 earnings estimates. Several other firms have also trimmed their price targets for Progyny. The company's future guidance for EPS is optimistic, but insider selling and institutional buying trends are mixed.
PGNY SEC Filings - Progyny, Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Progyny, Inc. (PGNY) SEC filings, including 10-K, 10-Q, and 8-K forms, along with AI-powered summaries and sentiment analysis. It details how these documents offer insights into Progyny's financial performance, material events, and risk factors, particularly within the healthcare plans sector. The page highlights the utility of AI summaries for quickly understanding key information, such as revenue from fertility benefits, client metrics, executive changes, and capital structure.
From 5 employers to 600: Progyny marks 10 years in family care
Progyny is celebrating its 10-year anniversary, highlighting its growth from 5 founding employers to over 600, covering 7.2 million lives globally. The company emphasizes its significant impact on women's health and family building, including 12% higher pregnancy rates per IVF transfer and 23% higher live birth rates compared to national averages. Progyny plans year-long initiatives to mark the milestone, including partnering with RESOLVE for National Infertility Awareness Week and participating in the NASDAQ Closing Bell Ceremony.
Progyny Commemorates 10 Years of Redefining Women’s Health and Family Building Care
Progyny is celebrating 10 years of transforming women's health and family building solutions, having supported over 470,000 members and expanded to serve 7.2 million lives globally. The company attributes its success to combining clinical expertise, innovation, and a personalized approach, leading to higher pregnancy rates, faster access to care, and significant cost savings. To mark the anniversary, Progyny is launching several initiatives, including lighting the Empire State Building orange during National Infertility Awareness Week and participating in the NASDAQ Closing Bell Ceremony.
Progyny (NASDAQ: PGNY) schedules virtual 2026 meeting; board, audit ratification on ballot
Progyny (NASDAQ: PGNY) has scheduled its 2026 virtual annual meeting for May 21, 2026, with a record date of March 27, 2026, and 78.3 million shares outstanding. Stockholders will vote on the election of three Class I directors, ratification of Ernst & Young LLP as the independent auditor, an advisory vote on executive compensation, and two amendments to the Certificate of Incorporation to eliminate certain supermajority voting requirements. The proposed amendments aim to streamline governance by changing the voting threshold for several corporate actions from two-thirds to a simple majority of outstanding shares.
Progyny (NASDAQ:PGNY) Sets New 52-Week Low - Here's Why
Progyny (NASDAQ:PGNY) stock hit a new 52-week low of $16.60 on Tuesday, despite positive analyst ratings and recent earnings beat. The company reported Q4 EPS of $0.48, exceeding expectations, and provided optimistic FY2026 guidance. While analysts maintain a "Moderate Buy" consensus with an average price target of $27.91, several recent price target cuts suggest some concerns.
Progyny, Inc. (NASDAQ:PGNY) Given Average Recommendation of "Moderate Buy" by Analysts
Thirteen analysts have given Progyny, Inc. (NASDAQ:PGNY) a "Moderate Buy" consensus rating, with an average 12-month price target of $27.91. While some firms have trimmed price targets, Jefferies maintained a $30 target. The company recently reported strong earnings, beating EPS and revenue estimates, and provided positive FY2026 guidance, despite recent insider share sales.
Vanguard realignment: Progyny (PGNY) Schedule 13G/A shows 0 shares
The Vanguard Group filed an Amended Schedule 13G/A for Progyny (PGNY), reporting zero beneficially owned shares, representing 0% of Progyny's common stock. This change is due to an internal realignment effective January 12, 2026, where certain Vanguard subsidiaries now report their holdings separately. The filing clarifies that Vanguard no longer has or is deemed to have beneficial ownership over these securities.
Fort Washington Investment Advisors Inc. OH Grows Position in Progyny, Inc. $PGNY
Fort Washington Investment Advisors Inc. OH increased its stake in Progyny, Inc. (PGNY) by 10.7% in the fourth quarter, now owning 1,834,104 shares valued at $47.1 million. The fertility benefits management company recently surpassed Q4 earnings estimates with $0.48 EPS and $318.4 million in revenue, and has provided positive guidance for FY2026. Despite insider selling, analysts maintain a "Moderate Buy" rating for Progyny with an average price target of $27.91.
Fort Washington Investment Advisors Boosts Stake in Progyny
Ohio-based Fort Washington Investment Advisors Inc. significantly increased its stake in Progyny, a fertility benefits management company, by 10.7% in Q4 2025. The firm now holds over 1.8 million shares worth approximately $47.1 million, reflecting its confidence in Progyny's growth potential. This move makes Fort Washington one of Progyny's largest institutional investors and highlights the increasing traction of family-building programs.
JPMorgan Chase & Co. Lowers Holdings in Progyny, Inc. $PGNY
JPMorgan Chase & Co. reduced its stake in Progyny, Inc. by 28.1% in the third quarter of 2025, now holding 888,721 shares worth approximately $19.1 million. This comes as other institutional investors like Vanguard Group increased their positions in the company. Progyny reported strong Q3 earnings, beating analyst expectations, and provided optimistic guidance for FY 2026, despite some analysts cutting price targets recently.
Progyny Inc stock faces uncertainty amid fertility benefits sector shifts and biotech peer pressures
Progyny Inc, a leader in employer-sponsored fertility benefits, is navigating evolving healthcare demands as US employers adjust benefits packages amid demographic shifts and rising infertility rates. The company's business model focuses on comprehensive family-building support through data-driven platforms, attracting attention from investors due to its role in a growing niche market, despite potential risks from economic downturns and increasing competition. Progyny's consistent revenue expansion, high gross margins, and strategic positioning make it a compelling long-term hold for investors bullish on healthcare demographics.
Progyny Inc stock faces uncertainty amid fertility benefits sector shifts and biotech peer pressures
Progyny Inc (PGNY) is navigating a dynamic fertility benefits sector, with the company positioned at the intersection of healthcare innovation and employee wellness amidst evolving employer priorities. The article highlights Progyny's business model, competitive advantages, and financial performance, while also addressing risks such as economic downturns and increasing competition. Despite potential headwinds, the company is seen as a compelling long-term hold for investors focused on healthcare demographics and corporate wellness trends.
Tudor Investment Corp ET AL Sells 221,184 Shares of Progyny, Inc. $PGNY
Tudor Investment Corp ET AL significantly reduced its stake in Progyny, Inc. by selling 221,184 shares, leaving them with 250,849 shares valued at $5.4 million. Despite this, other institutions like Vanguard and Ameriprise increased their holdings, and Progyny reported strong Q4 results, beating EPS and revenue estimates, with a "Moderate Buy" consensus rating from analysts. Insider selling activity was also noted, with EVP Allison Swartz selling 4,657 shares.
Trading the Move, Not the Narrative: (PGNY) Edition
This article analyzes Progyny Inc. (NASDAQ: PGNY), indicating a neutral sentiment across all time horizons and suggesting a wait-and-see approach for investors. It outlines institutional trading strategies including long, short, and breakout options, with specific entry points, targets, and stop losses. The analysis also highlights elevated downside risk due to a lack of additional long-term support signals.
Progyny, Inc. Investigated by the Portnoy Law Firm
The Portnoy Law Firm has launched an investigation into Progyny, Inc. (NASDAQ: PGNY) for potential securities fraud, encouraging investors to contact them regarding legal rights and possible class action. This follows a significant drop in Progyny's stock price on September 19, 2024, after the company disclosed losing a large client accounting for 12% of its total revenue, impacting 670,000 members. The firm is offering complimentary case evaluations for investors seeking to recover losses.
Barclays Cuts Progyny (NASDAQ:PGNY) Price Target to $23.00
Barclays has lowered its price target for Progyny (NASDAQ:PGNY) from $29.00 to $23.00, while maintaining an "overweight" rating, suggesting a potential upside of 27.5% from its current price. This adjustment follows Progyny's Q4 earnings beat with an EPS of $0.48 and revenue of $318.4M, surpassing estimates. Despite the reduced price target, analysts maintain a "Moderate Buy" consensus rating for PGNY with an average target price of $27.91.
Barclays cuts Progyny stock price target on membership concerns
Barclays has lowered its price target for Progyny Inc. (NASDAQ:PGNY) to $23 from $29, while maintaining an Overweight rating, citing concerns over membership revisions. Despite a positive outlook from Progyny's CEO regarding utilization and membership trends, the firm noted that it will take time for investor confidence to rebuild. Other analysts like Canaccord Genuity, Jefferies, BTIG, and KeyBanc have also adjusted their price targets downwards, yet Progyny reports stable business performance including high client retention.
Progyny (PGNY) Chief Product Officer has RSU shares withheld for taxes
Progyny, Inc.'s Chief Product Officer, Geoffrey Clapp, reported a tax-related disposition of 3,275 common shares on March 17, 2026. These shares, valued at $17.42 each, were withheld to cover taxes upon the vesting of restricted stock units. Following this event, Clapp directly holds 60,647 shares of Progyny common stock.
Assessing Progyny (PGNY) Valuation After Prolonged Share Price Weakness
Progyny (PGNY) has experienced prolonged share price weakness, with a significant decline over the past year, despite reporting annual revenue of US$1.29 billion and net income growth of 20.1%. While a DCF model suggests the stock is undervalued with a fair value of $30.91, its current P/E ratio is higher than industry averages, indicating potential valuation risk if growth expectations falter. The article encourages investors to review various signals and narratives to determine if the stock is a mispriced opportunity or if the market has already accounted for its future growth trajectory.
Progyny, Inc. $PGNY Shares Purchased by Algert Global LLC
Algert Global LLC increased its stake in Progyny, Inc. (NASDAQ:PGNY) by 35.1% in the third quarter, now owning 595,805 shares valued at $12,822,000. Other institutional investors like Principal Financial Group Inc. and Fort Washington Investment Advisors Inc. OH also significantly increased their holdings. Analysts currently rate Progyny as a "Moderate Buy" with a consensus price target of $28.45, despite some recent price target reductions and an insider stock sale by EVP Allison Swartz.
Progyny, Inc. (NASDAQ:PGNY) Sees Significant Growth in Short Interest
Progyny, Inc. (NASDAQ:PGNY) experienced a significant 28.3% increase in short interest during February, reaching 5,150,473 shares, which accounts for approximately 6.9% of its shares sold short. Despite this, the company reported strong Q4 results, beating EPS and revenue expectations, and provided positive FY2026 guidance. Analyst sentiment remains largely positive with a "Moderate Buy" consensus rating and an average price target of $28.45.
Progyny Announces Settlement, Governance Reforms on Director Pay
Progyny Inc. has announced a settlement in a shareholder derivative action regarding excessive non-employee director compensation since 2020. The agreement, subject to court approval, includes corporate governance reforms such as a new director compensation policy that caps annual awards and restricts other forms of director pay, benefiting the company and shareholders without direct monetary payouts to investors. This follows litigation alleging breach of fiduciary duty and unjust enrichment related to director compensation.
Progyny issues notice of settlement for derivative action regarding director pay
Progyny, Inc. (NASDAQ:PGNY) announced a settlement agreement for a derivative action concerning its historical compensation practices for non-employee directors. The legal challenge, filed in New York, addresses past compensation arrangements. The company filed the notice as an exhibit to its Form 8-K with the SEC, though specific settlement terms were not disclosed.
Proposed Progyny (NASDAQ: PGNY) director pay settlement adds governance reforms
Progyny, Inc. has announced a proposed settlement for a stockholder derivative action concerning historical non-employee director compensation practices. The settlement, awaiting court approval, introduces new corporate governance reforms for at least four years, including a cap on annual director compensation at $288,000 (comprising cash and equity) plus additional retainers for leadership roles. Stockholders will not receive direct monetary payments, but the company will pay $450,000 in attorneys' fees to the plaintiff's counsel.
(PGNY) Volatility Zones as Tactical Triggers
This article provides a detailed analysis of Progyny Inc. (NASDAQ: PGNY) using AI-generated volatility zones and tactical triggers. It outlines near, mid, and long-term signals, noting a neutral short-term sentiment and elevated downside risk. Three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—are presented with specific entry, target, and stop-loss levels.
Progyny issues notice of settlement for derivative action regarding director pay
Progyny, Inc. announced a settlement for a derivative action concerning its historical compensation practices for non-employee directors, resolving claims filed in the Supreme Court for the State of New York. The company filed a Notice of Pendency of Settlement of Derivative Action with the SEC, though specific terms were not disclosed. This news follows several analyst adjustments to Progyny's stock targets due to revised expectations for covered lives and Q1 2026 revenue guidance.
Progyny Issues Notice Of Pendency Of Settlement Of Derivative Action
Progyny has issued a notice regarding the pendency of a settlement related to a derivative action. The announcement is concise, provided by Refinitiv and Reuters, and indicates that further details would require logging in or creating an account.
Canaccord Genuity Group Lowers Progyny (NASDAQ:PGNY) Price Target to $19.00
Canaccord Genuity Group reduced its price target for Progyny (NASDAQ:PGNY) from $26.00 to $19.00, maintaining a "hold" rating, though the consensus among analysts remains a "Moderate Buy" with an average target of $28.45. This comes despite Progyny beating Q earnings estimates with an EPS of $0.48 versus $0.38 expected and revenue of $318.4 million. The company's shares traded down approximately 3.4% intraday following the news, and Progyny has also provided FY2026 guidance.
Progyny’s Dual Use of Buybacks and ESOP Shares Raises a Key Capital Allocation Question (PGNY)
Progyny reported strong Q4 and full-year 2025 results, with increased revenue and net income. The company issued 2026 revenue guidance, completed a significant share buyback, and filed for a shelf registration tied to its ESOP, signaling active capital management and employee ownership support. This article examines how these financial movements and updated revenue guidance influence Progyny's investment narrative.
Barclays PLC Purchases 696,447 Shares of Progyny, Inc. $PGNY
Barclays PLC significantly increased its stake in Progyny, Inc. (NASDAQ:PGNY) by 79.2% in the third quarter, acquiring an additional 696,447 shares. This brings their total holdings to 1,575,470 shares valued at $33.90 million. Other institutional investors also modified their positions, with 94.93% of the stock currently owned by institutions, while insiders have recently sold shares.
Progyny’s Dual Use of Buybacks and ESOP Shares Raises a Key Capital Allocation Question (PGNY)
Progyny recently reported strong Q4 2025 and full-year results, coupled with 2026 revenue guidance, a share buyback program, and an ESOP-related share registration. These actions highlight the company's active capital management and support for employee ownership, while investors assess the updated revenue outlook and its implications for Progyny's growth and risk factors, particularly client concentration. Analysts hold varying projections for future revenue and earnings, which influences the stock's fair value.
Quantbot Technologies Reduces Stake in Progyny
Quantbot Technologies LP has significantly reduced its stake in Progyny, Inc. by 68.6% in the third quarter of 2025, now owning 36,137 shares valued at $778,000. This divestment by the investment management firm could indicate a shift in investor sentiment regarding the fertility benefits company, although institutional ownership remains high. Investors will be observing Progyny's market position closely in the upcoming quarters.
Progyny (PGNY) CFO reports 339-share tax-withholding disposition on Form 4
Progyny, Inc.'s CFO, Mark S. Livingston, has filed a Form 4 detailing a tax-related disposition of 339 shares of company common stock. These shares, valued at $17.52 each, were withheld on March 4, 2026, to cover tax obligations upon the vesting of his restricted stock units. This transaction is characterized as a routine administration of stock-based compensation and not an open-market sale, leaving Livingston with 87,338 directly owned shares.
Progyny, Inc. Executives to Participate in Upcoming Investor Conferences
Progyny, Inc. announced that its executives will participate in several investor conferences in March. Mark Livingston (CFO) will attend the Leerink Partners Global Healthcare Conference, Pete Anevski (CEO) will be at the Barclays Global Healthcare Conference, and Melissa Cummings (COO) along with Pete Anevski will participate in the KeyBanc Capital Markets Healthcare Forum. Investors can access live audiocasts and replays of the fireside chat sessions on Progyny's investor relations website.
Jefferies Maintains Buy on PGNY (Progyny, Inc.) March 2026
Jefferies has maintained a "Buy" rating on Progyny, Inc. (PGNY) while lowering its price target from $36 to $30. This adjustment, made on March 6, 2026, reflects continued confidence in the company's long-term prospects in fertility benefits, tempered by caution regarding near-term execution risks and valuation. Meyka AI also rates PGNY with an "A" grade.
Progyny, Inc. Executives to Participate in Upcoming Investor Conferences
Progyny, Inc. announced that its executives will participate in several upcoming investor conferences in March. CFO Mark Livingston will speak at the Leerink Partners Global Healthcare Conference, while CEO Pete Anevski will participate in fireside chats at the Barclays Global Healthcare Conference and the KeyBanc Capital Markets Healthcare Forum. COO Melissa Cummings will also join a panel discussion at the KeyBanc event.
Progyny leaders hit March healthcare stages on fertility tech
Progyny executives will be participating in several investor conferences in March 2026, including the Leerink Partners Global Healthcare Conference, the Barclays Global Healthcare Conference, and the KeyBanc Capital Markets Healthcare Forum. CFO Mark Livingston, CEO Pete Anevski, and COO Melissa Cummings are scheduled to speak at various fireside chats and panel discussions covering topics related to women's health and fertility technology. Live audiocasts and replays of these sessions will be accessible on Progyny's investor relations website.
Progyny, Inc. Leadership to Participate in Key Investor Conferences in March 2026
Progyny, Inc. announced that its leadership team will participate in several investor conferences in March 2026, including the Leerink Partners Global Healthcare Conference, Barclays Global Healthcare Conference, and KeyBanc Capital Markets Healthcare Forum. CFO Mark Livingston and CEO Pete Anevski will present, while COO Melissa Cummings will join a panel. Live audiocasts of the events will be available on Progyny's investor relations website.
Progyny, Inc. Executives to Participate in Upcoming Investor Conferences
Progyny, Inc. announced that several of its leadership team members will participate in upcoming investor conferences in March 2026. CFO Mark Livingston, CEO Pete Anevski, and COO Melissa Cummings will be featured in fireside chats and panel discussions at the Leerink Partners Global Healthcare Conference, the Barclays Global Healthcare Conference, and the KeyBanc Capital Markets Healthcare Forum. Audiocasts of these sessions will be available on Progyny's investor relations website.
Progyny, Inc. Executives to Participate in Upcoming Investor Conferences
Progyny, Inc. announced that its executives will participate in several upcoming investor conferences in March 2026, including the Leerink Partners Global Healthcare Conference, the Barclays Global Healthcare Conference, and the KeyBanc Capital Markets Healthcare Forum. CFO Mark Livingston, CEO Pete Anevski, and COO Melissa Cummings will be presenting at these events, discussing topics related to the company's family building solutions and fertility technology. Live audiocasts and replays will be available on Progyny's investor relations website.
Progyny, Inc. (NASDAQ:PGNY) Given Average Rating of "Moderate Buy" by Brokerages
Progyny, Inc. (NASDAQ:PGNY) has received an average rating of "Moderate Buy" from twelve brokerages, with eight assigning a buy rating and four a hold rating. The average 12-month price target is set at $28.80. The company recently reported Q4 earnings of $0.48 EPS on $318.4 million revenue, beating estimates, and provided FY2026 and Q1 2026 guidance.
[Form 4] Progyny, Inc. Insider Trading Activity
Progyny, Inc. (PGNY) reported that its Chief Product Officer, Geoffrey Clapp, received new equity awards on March 2, 2026. These awards include 51,373 restricted stock units and a separate grant of 35,228 shares of common stock, totaling 86,601 shares, granted as annual merit incentives with no purchase price. The awards will vest over three years, with one-third vesting on the first anniversary and the remainder in quarterly installments, contingent on Clapp's continued service.
[Form 4] Progyny, Inc. Insider Trading Activity
Progyny, Inc.'s Chief Financial Officer, Mark S. Livingston, reported insider trading activity involving equity grants and tax-related share withholdings. He received significant grants of restricted stock units and stock options as annual merit awards and subsequently had shares withheld by the company to cover tax obligations upon RSU vesting. After these transactions, Livingston directly owns 87,677 common shares of Progyny, Inc.
Progyny, Inc. Hits New 52-Week Low at $16.75 Amid Declining Performance
Progyny, Inc. has reached a new 52-week low of $16.75, marking a 36.44% decline over the past year despite strong long-term fundamentals like high ROE and growth rates. The stock's underperformance relative to the S&P 500 and a decrease in promoter confidence are cited as key challenges. Market participants will closely monitor the company's financial metrics due to these concerns.
Allison Swartz to sell 4,657 PGNY shares (NASDAQ: PGNY) in vesting sale
Allison C. Swartz, associated with Progyny, Inc. (NASDAQ: PGNY), has filed a Form 144 to sell 4,657 shares of common stock due to restricted stock vesting on March 3, 2026. This filing also details past transactions including the sale of 530 shares on December 4, 2025, for $13,032.70, and 2,199 shares on March 2, 2026, for $37,976.73. Fidelity Brokerage Services LLC is listed as the broker for these transactions, which are described as routine insider dispositions.
JPMorgan Chase & Co. Trims Position in Progyny, Inc. $PGNY
JPMorgan Chase & Co. decreased its stake in Progyny, Inc. by 28.1% in the third quarter, selling 346,587 shares and retaining 888,721 shares valued at $19.13 million. Despite this trimming, Progyny exceeded quarterly earnings and revenue estimates and provided positive FY2026 guidance. The company maintains a "Moderate Buy" consensus rating from analysts, with institutional investors holding a significant 94.9% of its stock.
Short Interest in Progyny, Inc. (NASDAQ:PGNY) Increases By 41.0%
Short interest in Progyny, Inc. (NASDAQ:PGNY) increased significantly by 41% to 4.02 million shares in February, representing about 5.1% of the float. This rise in short interest comes despite the company reporting better-than-expected Q4 earnings and raising its full-year 2026 EPS guidance. However, a lower-than-anticipated Q1 revenue forecast led to a sell-off, with shares nearing their 12-month low.
